An immunotherapy drug called Tecentriq (atezolizumab) extended the survival of lung cancer patients for several months longer than chemotherapy and caused fewer side effects, according to a new study.
The findings are from an early analysis of 850 patients with non-small cell lung cancer in a phase 3 trial funded by the drug’s makers.
According to the American Cancer Society, non-small cell lung cancer is the major form of the disease, comprising up to 85 percent of cases. Lung cancer remains the leading cancer killer in the United States, with more than 158,000 people expected to die from the disease this year.
The patients in the new trial had run out of treatment options. They received either Tecentriq or the chemotherapy drug docetaxel — the standard treatment for this type of cancer.
Click here to Read the full article: Immune-Focused Drug Shows Promise Against Lung Cancer
Share this entry
- The American Health Council Appoints Dr. Akwasi Adjei to the Industry Board January 17, 2020
- The American Health Council Appoints Dr. Nelson Leung to the Physician Board January 17, 2020
- The American Health Council Appoints Ms. Karie Soost to the Physician Board January 17, 2020
- The American Health Council Appoints Mr. Gregory King to the Industry Board January 17, 2020
- The American Health Council Appoints Dr. Mitchell Pernal, DC to the Physician Board November 4, 2019
- The American Health Council Appoints Ms. Gretchen Lavergne to the Industry Board October 15, 2019